Diarrheagenic E. coli (DEC) is a major global cause of diarrheal diseases, with certain strains showing alarming levels of antibiotic resistance.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / February 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based det ...

When managing an irritated cornea, choosing among fortified antibiotics, oral antivirals, anti-inflammatories or combination ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The ...

Some bacteria have evolved to beat modern medication - but one natural kitchen cupboard item could be the key to stop them ...

Roorkee have uncovered a crucial regulatory mechanism in Acinetobacter baumannii -- a highly drug-resistant superbug ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The study, published in mBio, the journal of the American Society for Microbiology (ASM), reveals how the pathogen controls its attack and defense systems, paving the way for new treatment strategies.

They are becoming hard to treat, which has forced experts to act, according to a 2024 study. Vanderlei Bagnato, professor in the Department of Biomedical Engineering and senior author on the study, ...

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...